Phase 1b study of Prescient Therapeutics’ (ASX: PTX) PTX-100 shows excellent safety and promising efficacy in TCL patients
Prescient Therapeutics Limited (ASX: PTX) has shared encouraging PTX-100 Phase 1b study results. The findings were showcased...
